SNSW(688117.SH)

Last Updated 00:00:00
longbridge loading
Company Encyclopedia
View More
name
SNSW
688117.SH
ChengDu ShengNuo Biotec Co.,Ltd. engages in the research and development, production, sale, and export of peptide drugs. The company offers semaglutide, tirzepatide, retatrutide, cagrilintide, lanreotide, bivalirudin, epitifibatide, liraglutide; icatibant, octreotide, teriparatide, ziconotide, ganirelix, linaclotide, abaloparatide, terlipressin acetate; levosimendane, thymosin alpha, enfuvirtide, somatostatin, thymopentin, carbetocin, atosiban acetate, exenatide; and leuprorelin, degarelix, cetrorelix, plecanatide, and desmopressin acetate. ChengDu ShengNuo Biotec Co.,Ltd.
2.768 T
688117.SHMarket value -Rank by Market Cap -/-

Financial Score

21/05/2026 Update
B
PharmaceuticalsIndustry
Industry Ranking45/215
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreA
    • ROE16.95%A
    • Profit Margin22.11%A
    • Gross Margin59.87%A
  • Growth ScoreA
    • Revenue YoY49.42%A
    • Net Profit YoY119.62%A
    • Total Assets YoY20.64%A
    • Net Assets YoY16.40%B
  • Cash ScoreB
    • Cash Flow Margin83.29%C
    • OCF YoY49.42%A
  • Operating ScoreC
    • Turnover0.44C
  • Debt ScoreC
    • Gearing Ratio44.00%C

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    SNSW issued a profit warning, expecting a year-on-year increase of 100.53% in net profit attributable to the parent company for the first three quarters, reaching 145.10 million

    Zhitong·
    SH
    688117
    -1.33%
    Zhitong·
    SH
    688117
    -1.33%

    SNSW: Shareholders Chuanfa Investment, Lu Changliang, and Wang Xiaoli plan to collectively reduce their holdings by no more than 3.43%

    Zhitong·
    SH
    688117
    -1.33%
    Zhitong·
    SH
    688117
    -1.33%

    SNSW released its semi-annual performance report, with a net profit attributable to the parent company of 88.96 million yuan, a year-on-year increase of 308.29%

    Zhitong·
    SH
    688117
    -1.33%
    Zhitong·
    SH
    688117
    -1.33%

    SNSW: Acetate Ganirelix Injection has obtained a drug registration certificate

    Zhitong·
    SH
    688117
    -1.33%
    Zhitong·
    SH
    688117
    -1.33%

    Hong Kong Stock Concept Tracking | New Commercial Insurance Innovative Drug Directory Added! 2025 Medical Insurance Directory Adjustment Starts, Will Innovative Drugs Welcome a Historic Turning Point? (Including Concept Stocks)

    Zhitong·
    SH
    688117
    -1.33%
    HK
    01801
    +3.97%
    SH
    688076
    -1.23%
    Zhitong·
    SH
    688117
    -1.33%
    HK
    01801
    +3.97%
    SH
    688076
    -1.23%
    © 2026 Longbridge｜Disclaimer